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Background: Mutations in EFTUD2 were proven to cause a very distinct mandibulofacial dysostosis type Guion-Almeida
(MFDGA, OMIM #610536). Recently, gross deletions and mutations in EFTUD2 were determined to cause syndromic
esophageal atresia (EA), as well. We set forth to find further conditions caused by mutations in the EFTUD2 gene
(OMIM *603892).
Methods and results: We performed exome sequencing in two familial cases with clinical features overlapping with
MFDGA and EA, but which were previously assumed to represent distinct entities, a syndrome with esophageal atresia,
hypoplasia of zygomatic complex, microcephaly, cup-shaped ears, congenital heart defect, and intellectual disability in a
mother and her two children [AJMG 143A(11):1135-1142, 2007] and a supposedly autosomal recessive oto-facial
syndrome with midline malformations in two sisters [AJMG 132(4):398-401, 2005]. While the analysis of our exome data
was in progress, a recent publication made EFTUD2 mutations highly likely in these families. This hypothesis could be
confirmed with exome as well as with Sanger sequencing. Also, in three further sporadic patients, clinically overlapping to
these two families, de novo mutations within EFTUD2 were identified by Sanger sequencing. Our clinical and molecular
workup of the patients discloses a broad phenotypic spectrum, and describes for the first time an instance of germline
mosaicism for an EFTUD2 mutation.
Conclusions: The clinical features of the eight patients described here further broaden the phenotypic spectrum
caused by EFTUD2 mutations or deletions. We here show, that it not only includes mandibulofacial dysostosis type
Guion-Almeida, which should be reclassified as an acrofacial dysostosis because of thumb anomalies (present in 12/35
or 34% of patients) and syndromic esophageal atresia [JMG 49(12). 737-746, 2012], but also the two new syndromes,
namely oto-facial syndrome with midline malformations published by Mégarbané et al. [AJMG 132(4): 398-401, 2005]
and the syndrome published by Wieczorek et al. [AJMG 143A(11): 1135-1142, 2007] The finding of mild phenotypic
features in the mother of one family that could have been overlooked and the possibility of germline mosaicism in
apparently healthy parents in the other family should be taken into account when counseling such families.
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High-throughput sequencing facilitates discovery of the
molecular etiology of rare syndromes. The discovery of the
DHODH gene being causative for Miller syndrome [1] was
the first autosomal recessive condition to be clarified by
exome sequencing. Since then, causative genes for many
syndromes have been identified using such approaches.
In 2012, the EFTUD2 gene was found to cause a very
distinct condition with phenotypic overlap with Treacher
Collins syndrome, the mandibulofacial dysostosis type
Guion-Almeida (MFDGA) [2]. This condition was charac-
terized by microcephaly, a characteristic craniofacial ap-
pearance with upslanting palpebral fissures, microtia,
preauricular and buccal tags and intellectual disability
[3,4]. In the paper by Lines et al. [2] only five of twelve pa-
tients had anomalies of the thumbs. Because thumb
anomalies were reported in additional patients [5,6], it
appeared to be one component of the EFTUD2 pheno-
typic spectrum, and we suggested to reclassify MFDGA to
acrofacial dysostosis type Guion-Almeida (AFDGA) [7].
Although none of the initially published EFTUD2 muta-
tion carriers presented with esophageal atresia (EA),
Gordon et al. [8] reported on eight patients with EFTUD2
mutations, esophageal atresia and other features of
AFDGA.
This clearly demonstrated that the spectrum of the
phenotype is wider and more often complicated by in-
ternal malformations than previously suspected. Subse-
quently, EFTUD2 mutations were found in patients
showing hemifacial microsomia with EA or an asymmet-
ric crying face with EA that were previously diagnosed
with CHARGE or Feingold syndromes [6].
Here, we broaden the EFTUD2-associated phenotype
with the identification of mutations in two previously pub-
lished, apparently novel familial [9,10], and three sporadic
previously unpublished patients. We report on a very mild
phenotype in one female patient and describe for the first
time a family with suspected germline mosaicism.Methods
We obtained written informed consent from the families
for participation in this study. The study was performed
according to the Declaration of Helsinki protocols and
was approved by the local institutional review board (ethical
votum 12-5089-BO for CRANIRARE and 11-4878-BO
for FACE).
Exome sequencing and data analyses
Exome sequencing was performed on two different plat-
forms. Exome sequencing for patients 1, 2, and 6 was
performed on an Illumina HiSeq2000, whereas exome se-
quencing for patient 4 and 5 was performed on a SOLiD4
platform (Life Technologies, Carlsbad, CA, USA).For sequencing on the HiSeq 2000, in family 1 (pa-
tients 1 and 2) and patient 6, 1.2 μg genomic DNA was
fragmented for library preparation by adaptive focused
acoustics on a Covaris S220 (Covaris Inc., Woburn, MA,
USA) for 60 sec with a duty cycle of 10%, intensity of 5
and cycles per burst of 200. A library was generated on
fragmented DNA using the TruSeq Sample Preparation
Kit v2 (Illumina, San Diego, CA, USA) following the
low-throughput and gel-free method protocols.
Exome enrichment of Library fragments was performed
using the NimbleGen Human SeqCap EZ v3.0 KIT follow-
ing the manufacturer’s protocol and under consideration of
the Technical Note “Targeted sequencing with NimbleGen
SeqCap EZ Libraries and Illumina TruSeq DNA samples
Prep Kit” released by NimbleGen. All samples were
analysed on a Bioanalyzer using the Agilent DNA 1000 kit
(Agilent Technologies, Inc., Santa Clara, CA, USA) prior
to sequencing on an Illumina HiSeq2000 platform using
the paired-end sequencing protocol. Data analyses and fil-
tering was performed as described elsewhere [11].
For samples from patients 4 and 5 (family 2), library
preparation was started using 3 μg of genomic DNA.
Shearing of DNA was performed on a Covaris TM S2 sys-
tem. Enrichment of the exomes was done according to the
manufacturer’s protocol using Agilent’s SureSelect Human
All Exon v.2 Kit (50 Mb). Sequencing was performed on a
SOLiD4 sequencing platform from Life Technologies.
LifeScope software v2.1 from Life Technologies was used
to map color space reads along the hg19 reference genome
assembly. The DiBayes algorithm, with high-stringency
calling, was used for single-nucleotide variant calling.
The small Indel tool was used to detect small insertions
and deletions. Exome sequencing data were filtered as
described previously [12].
Sanger sequencing
Genomic DNA was extracted from blood samples, buc-
cal smear and urine using DNA extraction Kits (Flexi
Gene DNA Kit, Qiagen, Hilden, Germany).
For confirmation of the EFTUD2 mutations identified
by exome sequencing in patients 1 to 6 and for muta-
tion screening in patients 7 and 8 and the 14 mutation
negative patients (see Additional file 1: Table S2), ampli-
fication and sequence analysis of individual exons and
their flanking regions was done essentially as described
by Czeschik et al. [11]. The reference sequence for the
description of mutations in the cDNA sequence is
Ensembl: ENST00000426333/NCBI: NM_004247.3.
cDNA analysis
The samples were collected in Tempus Blood RNA
tubes (Applied Biosystems, Foster City, CA, USA) and
RNA was isolated using the Tempus Spin RNA Isolation
kit (Applied Biosystems) as recommended by the
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thesis using the Superscript VILO cDNA synthesis kit
(Invitrogen, Carlsbad, CA, USA) as recommended by
the supplier. The Primer 3 program (http://primer3.ut.ee)
was used to design PCR-primers e23F (e23F: 5’-T
TCAGTGAAGGACAGCATCG-3’) and e28R (e28R: 5’-T
GGGGTAATTGAGCACAACA-3’) (Sigma-Aldrich, St.
Louis, MO, USA), and the region covering exons 24–27 of
the EFTUD2 gene was PCR-amplified (expected product
size in wild-type transcript, 635 bp) using the JumpStart
REDTaqReadyMix PCR Reaction kit (Sigma-Aldrich) with
the following touch-down PCR condition: initial de-
naturation at 95°C (5 min), then 2 cycles of 95°C (20 s),
63°C (20 s), 72°C (20 s), 2 cycles of 95°C (20 s), 61°C
(20 s), 72°C (20 s), 2 cycles of 95°C (20 s), 59°C (20 s),
72°C (20 s), and 28 cycles of 95°C (20 s), 57°C (20 s), 72°C
(20 s). PCR-products were analysed on a 2% agarose gel
(Ultrapure TM Agarose, Invitrogen), purified using the
Illustra ExoStar 1-step kit (GE Healthcare Life Sciences,
Buckinghamshire, UK) and sequenced using the e23F and
e28R primers and the ABI PRISM BigDye Terminator
v.3.1 Cycle Sequencing Kit (Applied Biosystems). Frag-
ments were separated on an ABI3130XL Genetic Analyser
(Applied Biosystems) and the sequences were analyzed
using Sequencher version 5.0 (Ann Arbor, MI, USA).
Subcloning and sequence analysis
PCR-products were subcloned into the pCR-4 TOPO vec-
tor using the TOPO TA Cloning pCR-4-TOPO Vector kit
(Invitrogen) as recommended by the supplier. Clones were
analysed and selected for further analysis based on the size
of the insert, which was determined by direct colony PCR
analysis using the M13-20F and M13R primers (Invitrogen)
and the JumpStart REDTaqReadyMix PCR Reaction kit
(Sigma-Aldrich). PCR-products were analysed on a 2%
agarose gel (Ultrapure TM Agarose, Invitrogen), and se-
lected clones were grown overnight in selective medium
(LB containing 100 μg/ml ampicillin). Plasmid DNA was
isolated using the QIAprep spin Miniprep kit (Qiagen) and
approximately 200 ng of plasmid DNA was sequenced and
analyzed as above in both directions using the M13-20F
and M13R primers.
Results
The detailed clinical data are summarized in Table 1 and
the identified EFTUD2 mutations in Table 2.
Family 1 (patients 1–3)
This family was published as a new syndrome with
esophageal atresia, hypoplasia of the zygomatic complex,
microcephaly, cup-shaped ears, congenital heart defect
(ASD in patient 1 and VSD in patient 2), and mental re-
tardation [9]. We re-evaluated them in 2012, and the de-
tailed clinical data are depicted in Table 1: At this time,the elder daughter (patient 1) was 21 years old. She had
mild intellectual disability (ID). Her body measurements
were normal for height and weight [158 cm, -1.5 SD;
63 kg, 0.5 SD], but OFC was still low [51 cm, -3.7 SD].
She had the characteristic facial dysmorphism comprising
upslanting palpebral fissures, short philtrum and
downturned corners of the mouth (Figure 1A, B). The
previously described cup-shaped ears with thickened heli-
ces and squared earlobes were still present (Figure 1C).
Her younger brother (patient 2) was more severely af-
fected. He was re-examined at the age of 8 7/12 years. Short
stature [128 cm, -2.4 SD], low weight [25 kg, -2.4 SD] and
microcephaly [46 cm, -5.9 SD] were noted. He suffered
from moderate to severe ID. He attended a school for men-
tally handicapped children, he spoke single words only. As
mouth opening was severely restricted, he was still tube
fed. The craniofacial phenotype was also more severe in
him with upslanting palpebral fissures, small nose with hy-
poplastic alae nasi, short philtrum and microtia. The upper
part of the ear was more severely affected than the lower
part with squared earlobes (Figure 1D). The mother
(patient 3) appeared intellectually normal. She had a normal
head circumference, nasal speech and a scar on her right
cheek with underlying hypoplasia of the zygoma. Otherwise
she was completely healthy.
To find the molecular basis of this apparently distinct
entity, we decided to perform exome sequencing in both
affected siblings. During evaluation of our exome data, the
paper by Gordon et al. [3] was published, and thus an
EFTUD2 mutation was considered in this family as well.
Exome sequencing and confirmation by Sanger sequen-
cing revealed a new splice site mutation c.994+1G>C
in both siblings and their more mildly affected mother
(Figure 2A). We have not determined the consequence of
this splice site mutation experimentally, but the most
likely effect is a skipping of exon 11 in the mature mRNA
and a shift of the open reading frame that leads to a pre-
mature translation stop signal (pSer290Argfs*2). The clin-
ically suspected mosaicism of the mother due to her
milder clinical features could not be confirmed in her
DNA from blood, saliva and urine, as mutant and wildtype
peaks were about the same height as in the blood DNA of
her two affected children. We investigated four unaffected
family members (two siblings and two further children of
patient 3). They were all negative for the splice mutation.
Family 2 (patients 4 and 5)
These two sisters (patients 4 and 5) were published in
2005 as a new autosomal recessive syndrome with mid-
line defects [10]. Both presented with mild ID, micro-
cephaly, microtia with squared earlobes and cleft palate;
esophageal atresia was reported in one sister. According
to the original publication, they have seven healthy sib-
lings. Unfortunately, only a few current clinical details of
Table 1 Clinical data in patients with EFTUD2 mutations
Patient
1 [9]
Patient
2 [9]
Patient
3 [9]
Patient
4 [10]
Patient
5 [10]
Patient 6 Patient 7 Patient 8 Lines
et al. [2]
n=12
Bernier
et al. [5]
n=1
Gordon
et al. [8]
n=12
Need
et al. [15]
n=2
Luquetti
et al. [9]
n=3
Total
n=38
Sex F M F M F M M F 5 f/7 m n.r. 3 f/2 m* 2 m 3 m 13 f/17 m
Consanguinity - - - + + - - - 1/12 n.r. n.r. n.r. n.r. 3/38
Development
ID IQ 75 Severe - Mild Mild Moderate Moderate Mild 12/12 n.r. 8/9 2/2 2 mild/
1 severe
36/38
Age at
walking [mo]
16 39 n.r. 30 24 21 36 18 16-60 n.r. n.r. n.r. n.r. 16-60 mo
Age at first
words [mo]
16 - n.r. 36 30 30 24 12 24-30 n.r. n.r. n.r. n.r. 12-36 mo
Epilepsy - - - - - - +, Gener. - 5/10 n.r. 1/10 n.r. 2/3 9/31
Pregnancy
Polyhydramnios + + n.r. + + + - +++ n.r. n.r. 5/10 n.r. n.r. 11/17
Measurements
Gestational weeks at
birth
41 34 n.r. 40 40 40 38 37 33-42 n.r. 30.5-41 n.r. n.r.
Weight 3010/
-1.4
2010/
-0.4
n.r. 2500/-2.3 4000/1.3 3180/-1.0 3600/0.5 2900/mean -2.5 – 0.5 n.r. -2 – 1.5 n.r. 1 - -2 -2.5 – +1.5
Length 51/-0.8 n.r. n.r. 48/-1.7 n.r. 52/-0.2 49/-0.5 n.r. n.r. n.r. -2 – 0 n.r. n.r. -1.7 - mean
OFC 34/-0.6 n.r. n.r. 32/-2.2 n.r. 34/-1.2 34/-0.4 32.3/-1 SD -3.5 - -1.75 n.r. -3 – 0.5 n.r. 1 -2.2 – +0.5
Age at
examination [y]
21 8 7/12 Adult 8 2.5 7
4/12 3,5 4.5 1 – 13 4/12 n.r. 0.5 –
adult
2 and 8 n.r. 0.5 y - adult
Height 158/-1.5 128/-2.4 165/-0.2 114.5/-2.6 84.5/-1.91 126/0.1 98/0 100.7/-1.6 -2 – 1 SD n.r. -3 – 2 n.r. -1 -
-4 SD
-4 - +1
Weight 63/0.5 25/-2.4 58/-1.0 21/-1.6 11/-1.3 22.5/-0.6 14,6/-0.2 18.2/1 -4 – 0 SD n.r. -3 – 3 n.r. -4 – +3
OFC 51/-3.7 46/-5.9 53.5/-1.0 46/-5.5 43.4/-5.3 47.5/-3.9 45/-3.3 46.6/-3.3 -6 - -3 Microc. -3 – 1 Microc. Normal -5.9 –
Normal
Craniofacial
dysmorphism
Facial asymmetry - - + - - - - + (Mild) n.r. n.r. 7/10 1/2 3/3 13/23
Hyperplastic
supraorbital ridges
- - + + - + - n.r. n.r. n.r. n.r. n.r. 3/8
Frontal bossing - - + + - -/Sloping
forehead
- n.r. n.r. n.r. n.r. 0/2 2/4
Upslanting
palpebral fissures
+ - - + + + - - Down slanting n.r. n.r. n.r. n.r. 0/2 4/10
Epibulbar dermoid - - - - - - - - n.r. n.r. n.r. n.r. 1/3 1/11
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Table 1 Clinical data in patients with EFTUD2 mutations (Continued)
Microtia/with
squared earlobe
+/+ +/+ - +/+ +/+ + +/+ +/+ 11/11 n.r. 10/12 2/2 3/3 33/37
Preauricular tag - - - - - - + - 10/12 n.r. 4/12 n.r. 3/3 18/35
Preauricular pit - - - - - - + - n.r. n.r. n.r. n.r. n.r. 1/8
A-/hypoplasia of
external ear canal
- + - + - Narrow + +/+ 7/10 n.r. n.r. n.r. 3/3 15/21
Hearing loss bil.
cond.
bil.
comb.
- bil. cond. -. - + +, cond. 10/11 n.r. 11/12 2/2 3/3 31/37
Cleft Palate - + Nasal
speech
- + + - - 6/12 n.r. 2/12 ‘1/2 0/3 12/37
Reduced mouth
opening
+ + + n.r. n.r. - + + n.r. n.r. n.r. n.r. n.r. 5/7
Micrognathia + + - - + + + + 12/12 n.r. 10/12 n.r. 3/3 31/36
Malformations
Tracheostomy - + - - - - - + 1/12 n.r. n.r. n.r. n.r. 3/20
Esophageal atresia + + - + - + - + n.r. n.r. 8/12 n.r. n.r. 13/20
CHD ASD VSD - n.r. n.r. VSD - - 7/12 n.r. 3/12 ‘1/2 1/3 15/37
Scoliosis + - - n.r. n.r. n.r. - - n.r. n.r. n.r. n.r. n.r. 1/5
Cleft of zygomatic
bone
bil bil unil n.r. n.r. bil n.r n.r. n.r. n.r. n.r. n.r. 3/3 7/7
Choanal atresia - - - - - - - Stenosis not
atresia +
6/12 n.r. 2/12 n.r. 3/3 12/35
Inner/middle ear
malformations
n.r. n.r. n.r. Small middle
ear cavity,
abnormal
malleolus
Absence of
middle ear
pneum., hypopl.
malleus and incus
- n.r Small middle ear
cavity, normal
cochlea and
semicircular canals
n.r. n.r. n..r. n.r. 3/3 6/7
Anomalies
of hands
Proximally placed/
duplicated thumbs
- - - - - - Slightly proximal
placement
- 5/9 + 1/12 2/2 2/3 12/35
Clinodactyly V + - - n.r. n.r. - n.r. - n.r. n.r. n.r. n.r. n.r. 1/5
* Sex of the remaining patients was not indicated in the paper.
Abbreviations: ID intellectual disability, n.r. not reported, bil bilateral.
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Table 2 Summary of heterozygous EFTUD2 mutations in this report
Family 1 Family 2 Patient 6 Patient 7 Patient 8
Patients 1-3 Patients 4, 5
Genomic position* chr17:42949813 chr17:42929870 chr17:42957947 chr17:42929931 chr17:42961093
Nucleotide substitution# c.994+1G>C c.2622dupT c.594T>G c.2562-1G>C c.351-1G>A
Localization Intron 11 Exon 26 Exon 8 Intron 25 Intron 4
Amino acid substitution Predicted change: p.Ile875Tyrfs*10 p.Tyr198* p.Arg854Argfs*29 Predicted change:
skiping of exon 11 p.Arg854Argfs*76 Skipping. of exon 5
p.Ser290Argfs*2 p.Ala823–Gln859del p.Asp117Glufs*8
*Reference sequence for the genomic position is GRCh37/hg19 as of February 2009, and #reference sequence for the cDNA position is Ensemble:
ENST00000426333/NCBI: NM_004247.3.
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clinical re-examination: Both affected sisters had moder-
ate ID, the elder one was 18 years old and presented
with normal stature [155 cm, -1.6 SD] as well as her
younger sister, who was 12 years old [145 cm, -0.8 SD].
The craniofacial phenotype is depicted in Figure 3. The
parents gave consent for molecular analyses. ExomeFigure 1 Current photographs of patients published by Wieczorek et
palpebral fissures, downward corners of the mouth and microtia. Microgna
(D) Patient 2 at the age of 10 9/12 years with upslanting palpebral fissures,
squared earlobe. The patients and their parents gave informed consent tosequencing was performed in both sibs to identify the
underlying mutation. The previously undescribed het-
erozygous mutation c.2622dupT, p. Ile875Tyrfs*10 was
identified and confirmed by Sanger sequencing in this
patient and the affected sibling (Figure 2B). Both parents
and six unaffected siblings did not show this mutation.
Paternity was confirmed by AmpFLSTR Identifileral. [9]. (A, B, C) Patient 1 at the age of 21 years with upslanting
thia is not present anymore (no surgical correction performed).
micrognathia and microtia with dysplastic upper part of the ear and
publish the photographs.
c.994+1G>C
Patients 1 -3 
c.2622dupT
Patients 4 & 5
c.2562 -1G>C
Patient 7
c.351 -1G>A
Patient 8
c.594T>G
Patient 6
A
B
C
D
E
Figure 2 Electropherograms of EFTUD2 mutations. (A) Family 1. (B) Family 2. (C) Patient 6. (D) Patient 7. (E) Patient 8.
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germlinemosaicism in one of the parents was assumed.
Patient 6
This patient, a third boy in a sibship of three, has not
been described before. Pregnancy was complicated by
polyhydramnios. He was born at term with normal mea-
surements [weight: 3180 g, -1.0 SD; length: 52 cm, -0.2 SD;
OFC: 34 cm, -1.2 SD]. He presented with upslanting palpe-
bral fissures, bilateral microtia with squared earlobe, a bran-
chial tag, cleft soft palate and micrognathia (Figure 4 A,B).
Internal malformations consisted of esophageal atresia, ven-
tricular septal defect and bilateral clefts of the zygomaticbones (Figure 2A-C). He walked without support at the age
of 21 months and spoke his first words at 30 months. His
intellectual disability was mild, brain MRI was normal. Last
clinical examination was at age 7 4/12 years. He was still
microcephalic [OFC: 47.5 cm, -3.9 SD], height and
weight were normal [height: 126 cm, 0.1 SD; weight:
22.5 kg, -0.6 SD]. He had an abnormal hair implantation
with anterior displacement of the lateral hairline, a round
nasal tip, midface retraction, short philtrum and small teeth
(Figure 5 C,D). The ears were surgically corrected at the
age of 5 years. His limbs were completely normal.
As this patient was very similar to family 1, we performed
exome sequencing in this patient parallel to the siblings
Figure 3 Update of the craniofacial phenotype of the two sisters with oto-facial syndrome. (A, B) Elder sister at the age of 18 years with
receding forehead, large nose and mouth, bilateral microtia with hypoplasia especially of the upper part of the ear with squared earlobe.
(C, D) Younger sister at the age of 12 years with similar, but milder craniofacial dysmorphism.
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c.594T>G, p. Tyr198* was identified (Figure 2C) and con-
firmed by Sanger sequencing. The unaffected parents did
not carry the mutation.
Patient 7
This patient was also previously undescribed. He was the
second child of healthy parents. He was born after an un-
complicated pregnancy at 38 weeks of gestation. His birth
measurements were normal [weight: 3600 g, -0.5 SD;Figure 4 Zygomatic arch clefting of patient 6. Occipitomental view of t
(A). Corresponding computed tomography shows large cleft in the right (Blength: 49 cm, -0.5 SD; OFC: 34 cm, -0.4 SD). At 10
months, his features were microcephaly (41 cm, -3.75 SD],
sloping forehead, hyperplastic supraorbital ridges, bilateral
microtia with squared earlobes, and auricular fistulas,
aplasia of the external ear canal, hearing loss, high arched
palate, reduced mouth opening and micrognathia
(Figure 5E, F). A preauricular tag was removed in the new-
born period. He had no internal malformations. He
learned to walk without support at the age of 36 months
and spoke his first words at the age of 24 months. He washe skull shows only rudimentary development of the zygomatic arch
) and the left (C) zygomatic arch.
Figure 5 Craniofacial phenotype of three patients with de novo EFTUD2 mutations. (A, B) Patient 6 at the age of 12 months with round
face, mildly downslanting palpebral fissures, micrognathia and mild hypoplasia of the upper ear and squared earlobes. (C, D) Patient 6 at the age
of 7 4/12 years. Please note that the ears were surgically corrected. (E, F) Patient 7 at the age of 12 months with normal slant of palpebral fissures,
microtia and micrognathia. (G, H) Patient 7 at the age of 3.5 years with sloping forehead and microtia affecting the upper part of the ear in
particular. (I, J) Patient 8 at the age of 19 months with down-slanting palpebral fissure, microtia with squared earlobes, severe micrognathia and
tracheostomy. (K) Patient 8 at the age of 4.5 years. Upslanting palpebral fissures and severe micrognathia are still present.
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He had normal growth parameters [height: 98 cm, mean;
weight: 14.6 kg, -0.2 SD], but microcephaly [OFC: 45 cm,
-3.3 SD]. His thumbs were proximally placed, and he did
not use a normal ‘thumb-2nd finger grip’. Generalized sei-
zures were present and he was moderately intellectually
disabled. He spoke a few words, and used some sign lan-
guage. Receptive language was far better than spoken lan-
guage. The tentative diagnosis of a condition caused by an
EFTUD2 mutation was based on clinical grounds and
Sanger sequencing was performed. The splice mutation
c.2562-1G>C (Figure 2D) was detected in the child and
was not present in his unaffected parents. This mutation
has not been reported, previously.
In order to investigate the effect of the splice acceptor
site mutation, we analyzed parts of the EFTUD2 cDNA
that was synthesized from RNA isolated from blood
leucocytes as described in Methods. Because we obtained
more than the two expected PCR products (wild-type, wt,
and one mutant, mt), we subcloned the PCR products,
and identified clones with four different insert sizes of 635
bp (wt), 619 bp (mt1), 524 bp (mt2) and 481 bp (mt3), re-
spectively. As estimated from the agarose gel analysis of
the RT-PCR products (not shown), mt1 appears to repre-
sent the most abundant mutant transcript. Sequence ana-
lyses of representative clones (Figure 6) revealed that mt1
originated from a mutant transcript that is missing the
first 16 bases of exon 26, only, indicating that the exon 26
internal CAG was used as an alternative splice site. Themutant mt2 originated from a transcript that is missing
the entire exon 25 plus the first 16 bases of exon 26 (111
bp), and mt3 represents a mutant transcript that lacks
the entire exon 26 (154 bp). Whereas mt1 and mt3
would result in shifts of the open reading frame of the
respective mRNAs and premature translation stop co-
dons (p.Arg854Argfs*76 and p.Arg854Argfs*29), mt2
should result in an in-frame deletion of 37 amino acids
(p.Ala823–Gln859del). These amino acids are highly
conserved (100% identity) between many species from
puffer fish to mammals, and thus, this internal deletion
of amino acids must be considered pathogenic like the
frame-shift associated truncations.
Patient 8
This female was the first child of her non-consanguineous
parents, who subsequently had an unaffected daughter.
The pregnancy was complicated by polyhydramnios and
an amniotic fluid drainage procedure was undertaken at
34 weeks. At birth, she was noted clinically to have severe
micrognathia and upper airway obstruction. Detailed
examination showed an esophageal atresia, tracheo-
esophageal fistula and bilateral choanal atresia, which
required the insertion of a tracheostomy, still in situ at age
4.5 years. First examined clinically by a geneticist at day 3
of life, the striking features were the extreme micrognathia
and the low set ears, with a “squared off” appearance
(Figure 5I, J). The head circumference at birth was normal,
32.7 cm at 37 weeks gestation (−1 SD) but progressively
mt1mt2 mt3
exon 24 exon 25 exon 25 exon 26 exon 26 exon 27
exon 25 exon 27exon 25 exon 26-16bpexon 24 exon 26-16bp 
clone
wt
mt
Figure 6 Expression analysis of the mutant EFTUD2 allele of patient 7 with a splice site mutation, c.2562-1G>C. Part of the EFTUD2
transcript was amplified, products were subcloned, and individual clones sequenced (see Methods). Four different clones were identified,
representing the wild-type allele and three different splice products from the mutant allele. The splice junctions of the wild type (wt, upper row)
and of the mutant splice products (mt1, mt2, mt3, lower row) are depicted.
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SD), 44.8 cm at 3 years (−3.3 SD) and 46 cm at 4.5 years
(−3.3 SD). Ophthalmological assessment was normal, as
was cardiac assessment.
Motor development was encouraging. She walked at 18
months and developed several words with the use of a
speaking valve. Moreover, she has learned to sign effect-
ively, and that is her main form of communication at age
4.5 years. A psychological assessment at age 4 suggested
that language reception was excellent and the problem
solving capacity was at or above normal levels. The clinical
signs at age 4.5 years remained unchanged, with the ears
being small and malformed, especially in the upper helices
(Figure 5K), very noteworthy micrognathia, for which sur-
gical advance was planned, and downslanting palpebral
fissures. There was slight facial asymmetry.
Investigations had shown normal karyotype and FISH
22q, normal SNP array and normal TCOF1 mutation ana-
lysis. High resolution axial CT scan of the petrous tem-
poral bones showed small ear canals, reduced middle ear
cavities, which were fluid filled, and symmetrical but small
facial bones. The cochlea and semicircular canal anatomy
was essentially normal. Mutation testing of the EFTUD2
gene showed an intron 4 splice site mutation c.351-1G>A
(Figure 2E), which was shown to be de novo. We have not
determined the consequence of this splice site mutation
experimentally but the most likely consequence is a skip-
ping of exon 5 in the mature mRNA and a shift of the
open reading frame that leads to a premature translation
stop signal (pAsp117Glufs*8).
We sequenced an additional 14 patients with a phenotype
overlapping with the previously published patients. Those
patients had syndromic esophageal atresia (3/14), micro-
cephaly (8/14), thumb anomalies (1/14), microtia (8/14) =
and/or hemifacial microsomia (10/14). However, we could
not identify any EFTUD2 mutation in them. Detailed clin-
ical data are listed in Additional file 1: Table S2 and the cra-
niofacial phenotype is shown in Additional file 1: Figure S1.Discussion
The EFTUD2 (elongation factor Tu GTP-binding domain
containing 2) gene encodes U5-116 kD (U5 snRNP-
specific protein, 116-KD), a highly conserved spliceosomal
GTPase with striking sequence similarity to the ribosomal
translation elongation factor EF-2 [13]. Better known is the
S. cerevisiae ortholog of U5-116 kD, the Snu114p. Häcker
et al. could show that the Snu114p occupies a central pos-
ition within the U4/U6-U5 tri-snRNP particle [14]. Fabrizio
et al. concluded that the GTP-binding domain of the U5-
116 kD protein plays an important role in either the spli-
cing process itself or the recycling of spliceosomal snRNPs
[13]. The broad spectrum of clinical anomalies in patients
with EFTUD2 mutations is in agreement with the general
cellular function of U5-116 kD protein.
To the best of our knowledge, only six reports on
EFTUD2 mutations/deletions including this report have
been published [2,5,6,8,15]. Thirty-one different mutations
and four deletions comprising part of or the entire
EFTUD2 gene in a total of 35 non-related patients have
been reported so far. The mutations are spread throughout
the entire gene and comprise seven missense mutations,
eight splice site mutations, seven nonsense mutations and
seven frameshift mutations (Additional file 1: Table S2).
For two intronic mutations the causality remained elusive
[8]. There is no recurrent mutation. Haploinsufficiency is
the assumed pathogenic mechanism resulting from these
mutations [2].
We analyzed whether there is a correlation between
the severity of clinical findings and the type or location
of the mutation within the gene by adding characteristic
clinical findings of all published patients to Additional
file 1: Table S1. One can conclude that there is no obvi-
ous correlation, which makes it impossible to predict the
phenotypic outcome in mutation carriers. All but three
out of 35 individuals with EFTUD2 mutation were the
only affected individual in their families. For the first
time, we report an unusually mild EFTUD2 phenotype in
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and a son [1]. In the absence of further reports on simi-
larly mild EFTUD2 manifestations it is tempting to specu-
late that her phenotype resulted from somatic and
germline mosaicism in critical tissues despite the presence
of a seemingly heterozygous mutation in the investigated
blood, saliva and urine specimen. However, alternatively
she might also define a milder EFTUD2 spectrum or carry
favorable additional gene variants, which in part rescue
the usually more deleterious consequences of EFTUD2
haploinsufficiency.
There was another familial case with EFTUD2 muta-
tion published by Gordon et al. [8]. In this family, the
mother was also more mildly affected than her daughter,
but she had typical findings of EFTUD2 mutation car-
riers [8]. However, in all but one patient establishment
of diagnosis was possible because of the recognizable
clinical phenotype.
Polyhydramnios appears to be a prenatal indicator for
a more severe phenotype including esophageal atresia
and might potentially guide delineation from prenatal
Treacher Collins syndrome and further prenatal molecu-
lar genetic workup. In addition, if esophageal atresia is
prenatally diagnosed one should carefully evaluate the
fetus for signs of mandibulo- or acrofacial dysostoses.
In family 2 of this report, which was first clinically de-
scribed by Mégabarné et al. [10], the parents were
healthy and did not carry the mutation of their two af-
fected children. As family testing confirmed paternity,
one of the parents very likely has germline mosaicism,
indicating that germline mosaicism should be taken into
account when counseling families with apparently
de novo EFTUD2 mutation in one of the children.Conclusions
The phenotype in patients with EFTUD2 mutations is
much broader than previously anticipated. We suggest
renaming the phenotype Mandibulofacial Dysostosis, type
Guion-Almeida to Acrofacial Dysostosis Guion-Almeida
(AFDGA), because 12 of 35 patients in this study had
thumb anomalies. In addition to AFD type Guion-Almeida
and syndromic esophageal atresia, oto-facial syndrome also
belongs to the EFTUD2 mutation spectrum. The clinical
phenotype can be very mild as reported in the mother doc-
umented by Wieczorek et al. [9]. For the first time prelim-
inary evidence for germline mosaicism is presented in a
family published by Mégarbarné et al. [10], which has im-
portant implications for genetic counseling.
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